You are here: Industry Insights > M&A

News List

Will Other Pharmaceutical Enterprises Follow Up after the Large-scale Acquisitions of “New Takeda” and “New BMS” that may Yield Successful Results? PharmaSources/Zhixing
January 28, 2019
The acquisitions between similar pharmaceutical enterprises today may become an important way for pharmaceutical enterprises to gain core competence.
Roche says 'no thanks' to megadeals, but don't count out smaller M&A fiercepharma
January 23, 2019
After two recent, huge tie-ups between Takeda and Shire and Bristol-Myers Squibb and Celgene, megamergers seem to be a biopharma trend. But Roche isn't interested in it, its chairman said.
Congressmen to regulators: BMS-Celgene merger will stifle competition and raise drug prices fiercepharma
January 16, 2019
Biopharma experts predicting an M&A boom this year said one thing might thwart that surge of dealmaking: federal action on drug prices. If buyers can't charge what they want for the drugs they pick up in a merger, then the value of that deal could quickly
Lilly’s CEO looks to M&A, but not for CAR-T or gene therapies pharmaphorum
January 15, 2019
Eli Lilly’s CEO David Ricks could sign more deals to strengthen its pipeline of cancer drugs, but is leaving gene cell-based CAR-T oncology drugs and rare disease gene therapies for others to develop......
Takeda’s Shire takeover could herald new era of pharma M&A pharmaphorum
January 10, 2019
Takeda has officially taken over Shire in a deal that could re-establish the trend for mega mergers in big pharma.
Eli Lilly grabs spotlight at J.P. Morgan with $8B Loxo Oncology buyout fiercepharma
January 08, 2019
On the first day of biopharma’s largest confab, the J.P. Morgan Healthcare Conference, Eli Lilly confirmed that big-ticket M&A is back in fashion in the industry.
Verily pockets $1B with eyes on partnerships, M&A fiercebiotech
January 07, 2019
Six weeks after canning its Novartis-partnered glucose-sensing contact lens project, Verily is raising a $1 billion round that will power new partnerships, “global business development opportunities” and potential acquisitions.....
The top 10 medtech companies of 2024 fiercebiotech
January 03, 2019
While most of the world’s top 10 medtech companies are expected to defend their relative rankings in the coming years, ambitious or inspired M&A deals could give companies lower on the list the oomph to move up and ......
Bristol-Myers Squibb nears $1.6B sale of OTC unit Upsa to Taisho: report fiercepharma
January 03, 2019
Amid an industrywide shift away from the sector, Bristol-Myers Squibb is close to becoming the latest Big Pharma to exit consumer health. And word is Japan’s Taisho will be the one to help the company do it.
Clovis should put itself up for sale, activist Armistice says: report fiercepharma
December 26, 2018
Even before GlaxoSmithKline laid out an eye-popping $5.1 billion to buy PARP drugmaker Tesaro earlier this month, analysts were speculating that PARP rival Clovis Oncology would be a prime acquisition target.

Previous page 1 2 3 4 5 6 7 Next page